Results 91 to 100 of about 18,384 (210)

Composite lymphoma composed of follicular lymphoma and nodal T-follicular helper cell lymphoma: report of 3 cases highlighting histopathologic zonation of each neoplastic component. [PDF]

Am J Clin Pathol
Zhao Y, Hajjali I, Ju Y, Carrillo L, Feng M, Dong Q, Chen D, Siddiqi I, Wang E.   +8 more
europepmc   +1 more source

Composite Lymphoma: Opposite Ends of Spectrum Meet. [PDF]

J Clin Med Res, 2017
Khan U, Hadid T, Ibrar W, Sano D, Al-Katib A.   +4 more
europepmc   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Recurrent Composite Lymphoma in an Elderly Man: A Case of Marginal Zone Lymphoma With Classic Hodgkin Features Treated With Brentuximab and Immunotherapy. [PDF]

Cureus
Daniyal M, Polani A, Kumar A, Raja A, Canary M.   +4 more
europepmc   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

BCL2-Rearrangment-Negative CD23+ Follicle Center Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case of Biclonal Composite Lymphoma. [PDF]

Cureus
Qadir H, Palathingal Bava E, Gomez-Gelvez J, Liu W, Inamdar K, Wey E, Carey J, Shen Y, Kuriakose P, Ghosh S.   +9 more
europepmc   +1 more source

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma. [PDF]

Diagn Pathol, 2018
Moore AM, Moshkin O, Swain GJ, Crocker S, LeBrun DP.   +4 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Composite Lymphoma after Treatment with Infliximab for Sarcoidosis and Ankylosing Spondylitis. [PDF]

Intern Med
Furusawa H, Shimada S, Sawada A, Tanaka K, Yamamoto K, Miyazaki Y.   +5 more
europepmc   +1 more source

Relationship between continuous infusion meropenem PK/PD target attainment and C‐reactive protein dynamics in onco‐haematologic patients with febrile neutropenia

British Journal of Clinical Pharmacology, EarlyView.
Aim Meropenem is a second‐line antimicrobial agent in the treatment of febrile neutropenia in onco‐haematological patients. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between meropenem exposure and C‐reactive protein (C‐RP) over time was conducted.
Chun Liu, Pier Giorgio Cojutti, J. G. Coen van Hasselt, Michele Bartoletti, Maddalena Giannella, Pierluigi Zinzani, Pierluigi Viale, Federico Pea   +7 more
wiley   +1 more source